MK-0616是由默沙东(Merck & Co.)研发的全球首个口服PCSK9抑制剂,属于大环肽类药物,主要用于治疗高胆固醇血症及动脉粥样硬化性心血管疾病。其核心作用机制是通过特异性结合PCSK9蛋白,阻断其与低密度脂蛋白受体(LDL-R)的相互作用,从而减少LDL-R的降解,促进血液中低密度脂蛋白胆固醇(LDL-C)的清除。这一机制与现
MK-0616 was generally well tolerated and reduced LDL-C across all dose levels compared to placebo Merck plans to start Phase 3 pivotal study in the second half of 2023 RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD ...
除了肿瘤学之外,Davis还上调了默克公司对其心脏代谢候选药物30年代中期的销售预期,从超过100亿美元上调至约150亿美元。默克公司于2023年启动了多项3期试验:更新后的预期包括MK-6024,一种GLP-1/胰高血糖素受体双重激动剂,已进入治疗非酒精性脂肪性肝炎(MASH)的2b期临床。它还增加了对sotatercept和MK-0616的信心,so...
(MK-0616) Cardiovascular Hypercholesterolemia Peptide ifinatamab deruxtecan (MK-2400) Oncology Small cell lung cancer Esophageal cancer Biliary Tract Cancer Bladder cancer Breast cancer Cervical cancer Colorectal cancer Endometrial cancer Hepatocellular carcinoma ...
3.口服PCSK9抑制剂预计8月就启动3期:We are advancing our broad cardiovascular program. Enrollment in Phase 3 trials for MK-0616, our oral PCSK9 inhibitor, is anticipated to start later this month. 4. 科伦的TROP2ADC在准备开肺癌3期:We are advancing the broad clinical development program for th...
【医学同传前沿】本周三个Merck/MSD的临床试验研究者会议同传,涉及的药物有MK-6024、MK-8521、MK-1462、Sotorasib、Adagrasib、LY3537982、Pembrolizumab、GDC-6036 (divarasib)、MK-1084、Statin、Bempedoic Acid、MK-0616,核心药物MK-6024、MK-1084、MK-0616,药物类别KRAS G12C抑制剂、GLP-1-based Co-agonists...
PBMK04710 B300K 47MM HIGH FLUX 10PK PBMK06210 B300K 63.5MM HIGH FLUX 10PK PBMK07610 B300K 76MM HIGH FLUX 10PK PBMK09005 B300K 90MM HIGH FLUX 5PK PBMK15005 B300K 150MM HIGH FLUX 5PK PBQK02510 B50K 25MM HIGH FLUX 10PK PBQK04310 B50K 44.5MM HIGH FLUX 10PK. PBQK04710 B50K ...
PBMK04710 B300K 47MM HIGH FLUX 10PK PBMK06210 B300K 63.5MM HIGH FLUX 10PK PBMK07610 B300K 76MM HIGH FLUX 10PK PBMK09005 B300K 90MM HIGH FLUX 5PK PBMK15005 B300K 150MM HIGH FLUX 5PK PBQK02510 B50K 25MM HIGH FLUX 10PK PBQK04310 B50K 44.5MM HIGH FLUX 10PK. PBQK04710 B50K ...
2023年,默沙东针对Keytruda新开了多项联合治疗III期临床研究,其中包括与肿瘤mRNA疫苗V940(mRNA-4157)联合治疗非小细胞肺癌(NSCLC)的两项研究,以及与TROP2 ADC新药MK-2870(从科伦博泰引进)联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力,默沙东还计划通过增补肿瘤产品管线进一步丰富产品群...
水是实验室的通用试剂,常作为实验溶剂中 99% 的成分,因此水质是实验成功与否的关键。默克密理博以反渗透水、蒸馏水、去离子水或 Elix 预处理的先进技术,为水质要求严格的实验